Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126504791 | 12650479 | 1 | I | 201601 | 20160810 | 20160815 | 20160815 | EXP | FR-ASTRAZENECA-2016SE86928 | ASTRAZENECA | 921.00 | MON | F | Y | 0.00000 | 20160815 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126504791 | 12650479 | 1 | PS | ONGLYZA | SAXAGLIPTIN HYDROCHLORIDE | 1 | Oral | Y | U | 22350 | 1 | DF | TABLET | QD | |||||
| 126504791 | 12650479 | 2 | SS | STAGID | METFORMIN PAMOATE | 1 | Oral | Y | U | 0 | 700 | MG | TID | ||||||
| 126504791 | 12650479 | 3 | SS | NOVONORM | REPAGLINIDE | 1 | Oral | Y | U | 0 | 2 | DF | TID | ||||||
| 126504791 | 12650479 | 4 | SS | NOVONORM | REPAGLINIDE | 1 | Oral | Y | U | 0 | 1 | MG | QD | ||||||
| 126504791 | 12650479 | 5 | SS | NOVONORM | REPAGLINIDE | 1 | Oral | Y | U | 0 | 1 | MG | BID | ||||||
| 126504791 | 12650479 | 6 | SS | ALDACTONE | SPIRONOLACTONE | 1 | Oral | Y | 0 | 1 | DF | QD | |||||||
| 126504791 | 12650479 | 7 | C | SIMVASTATIN. | SIMVASTATIN | 1 | 0 | ||||||||||||
| 126504791 | 12650479 | 8 | C | AVLOCARDYL | PROPRANOLOL HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126504791 | 12650479 | 9 | C | TRIATEC | RAMIPRIL | 1 | 0 | ||||||||||||
| 126504791 | 12650479 | 10 | C | KARDEGIC | ASPIRIN LYSINE | 1 | 0 | ||||||||||||
| 126504791 | 12650479 | 11 | C | LANTUS | INSULIN GLARGINE | 1 | 0 | ||||||||||||
| 126504791 | 12650479 | 12 | C | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | 0 | ||||||||||||
| 126504791 | 12650479 | 13 | C | LERCAN | LERCANIDIPINE | 1 | 0 | ||||||||||||
| 126504791 | 12650479 | 14 | C | DOLIPRANE | ACETAMINOPHEN | 1 | 0 | ||||||||||||
| 126504791 | 12650479 | 15 | C | DUROGESIC | FENTANYL | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126504791 | 12650479 | 1 | Type 2 diabetes mellitus |
| 126504791 | 12650479 | 2 | Type 2 diabetes mellitus |
| 126504791 | 12650479 | 3 | Type 2 diabetes mellitus |
| 126504791 | 12650479 | 4 | Type 2 diabetes mellitus |
| 126504791 | 12650479 | 5 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126504791 | 12650479 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126504791 | 12650479 | Abdominal pain | |
| 126504791 | 12650479 | Diarrhoea |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126504791 | 12650479 | 1 | 20160309 | 0 | ||
| 126504791 | 12650479 | 2 | 20160309 | 0 | ||
| 126504791 | 12650479 | 3 | 20160309 | 0 | ||
| 126504791 | 12650479 | 4 | 20160311 | 20160313 | 0 | |
| 126504791 | 12650479 | 6 | 20160309 | 0 |